The Parkinson's disease death rate: carbidopa and vitamin B6
Marty Hinz,1 Alvin Stein,2 Ted Cole31Clinical Research, NeuroResearch Clinics, Inc., Cape Coral, FL, USA; 2Stein Orthopedic Associates, Plantation, FL, USA; 3Cole Center for Healing, Cincinnati, OH, USAAbstract: The only indication for carbidopa and benserazide is the management of L-3,4-dihydroxyp...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/87d24a3a33724faa8d5da050db49656d |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:87d24a3a33724faa8d5da050db49656d |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:87d24a3a33724faa8d5da050db49656d2021-12-02T08:11:19ZThe Parkinson's disease death rate: carbidopa and vitamin B61179-1438https://doaj.org/article/87d24a3a33724faa8d5da050db49656d2014-10-01T00:00:00Zhttp://www.dovepress.com/the-parkinson39s-disease-death-rate-carbidopa-and-vitamin-b6-peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438 Marty Hinz,1 Alvin Stein,2 Ted Cole31Clinical Research, NeuroResearch Clinics, Inc., Cape Coral, FL, USA; 2Stein Orthopedic Associates, Plantation, FL, USA; 3Cole Center for Healing, Cincinnati, OH, USAAbstract: The only indication for carbidopa and benserazide is the management of L-3,4-dihydroxyphenylalanine (L-dopa)-induced nausea. Both drugs irreversibly bind to and permanently deactivate pyridoxal 5'-phosphate (PLP), the active form of vitamin B6, and PLP-dependent enzymes. PLP is required for the function of over 300 enzymes and proteins. Virtually every major system in the body is impacted directly or indirectly by PLP. The administration of carbidopa and benserazide potentially induces a nutritional catastrophe. During the first 15 years of prescribing L-dopa, a decreasing Parkinson's disease death rate was observed. Then, in 1976, 1 year after US Food and Drug Administration approved the original L-dopa/carbidopa combination drug, the Parkinson's disease death rate started increasing. This trend has continued to the present, for 38 years and counting. The previous literature documents this increasing death rate, but no hypothesis has been offered concerning this trend. Carbidopa is postulated to contribute to the increasing Parkinson's disease death rate and to the classification of Parkinson's as a progressive neurodegenerative disease. It may contribute to L-dopa tachyphylaxis.Keywords: L-dopa, levodopa, vitamin B6, pyridoxal 5'-phosphateHinz MStein ACole TDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2014, Iss default, Pp 161-169 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Therapeutics. Pharmacology RM1-950 |
| spellingShingle |
Therapeutics. Pharmacology RM1-950 Hinz M Stein A Cole T The Parkinson's disease death rate: carbidopa and vitamin B6 |
| description |
Marty Hinz,1 Alvin Stein,2 Ted Cole31Clinical Research, NeuroResearch Clinics, Inc., Cape Coral, FL, USA; 2Stein Orthopedic Associates, Plantation, FL, USA; 3Cole Center for Healing, Cincinnati, OH, USAAbstract: The only indication for carbidopa and benserazide is the management of L-3,4-dihydroxyphenylalanine (L-dopa)-induced nausea. Both drugs irreversibly bind to and permanently deactivate pyridoxal 5'-phosphate (PLP), the active form of vitamin B6, and PLP-dependent enzymes. PLP is required for the function of over 300 enzymes and proteins. Virtually every major system in the body is impacted directly or indirectly by PLP. The administration of carbidopa and benserazide potentially induces a nutritional catastrophe. During the first 15 years of prescribing L-dopa, a decreasing Parkinson's disease death rate was observed. Then, in 1976, 1 year after US Food and Drug Administration approved the original L-dopa/carbidopa combination drug, the Parkinson's disease death rate started increasing. This trend has continued to the present, for 38 years and counting. The previous literature documents this increasing death rate, but no hypothesis has been offered concerning this trend. Carbidopa is postulated to contribute to the increasing Parkinson's disease death rate and to the classification of Parkinson's as a progressive neurodegenerative disease. It may contribute to L-dopa tachyphylaxis.Keywords: L-dopa, levodopa, vitamin B6, pyridoxal 5'-phosphate |
| format |
article |
| author |
Hinz M Stein A Cole T |
| author_facet |
Hinz M Stein A Cole T |
| author_sort |
Hinz M |
| title |
The Parkinson's disease death rate: carbidopa and vitamin B6 |
| title_short |
The Parkinson's disease death rate: carbidopa and vitamin B6 |
| title_full |
The Parkinson's disease death rate: carbidopa and vitamin B6 |
| title_fullStr |
The Parkinson's disease death rate: carbidopa and vitamin B6 |
| title_full_unstemmed |
The Parkinson's disease death rate: carbidopa and vitamin B6 |
| title_sort |
parkinson's disease death rate: carbidopa and vitamin b6 |
| publisher |
Dove Medical Press |
| publishDate |
2014 |
| url |
https://doaj.org/article/87d24a3a33724faa8d5da050db49656d |
| work_keys_str_mv |
AT hinzm theparkinson39sdiseasedeathratecarbidopaandvitaminb6 AT steina theparkinson39sdiseasedeathratecarbidopaandvitaminb6 AT colet theparkinson39sdiseasedeathratecarbidopaandvitaminb6 AT hinzm parkinson39sdiseasedeathratecarbidopaandvitaminb6 AT steina parkinson39sdiseasedeathratecarbidopaandvitaminb6 AT colet parkinson39sdiseasedeathratecarbidopaandvitaminb6 |
| _version_ |
1718398610593284096 |